Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020113877 - FUNCTION AND USE OF E2F6 INHIBITOR

Publication Number WO/2020/113877
Publication Date 11.06.2020
International Application No. PCT/CN2019/081984
International Filing Date 10.04.2019
IPC
A61K 48/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
A61K 45/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
A61K 39/395 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61K 38/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
CPC
A61K 31/4188
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
41641,3-Diazoles
4188condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
A61K 31/7088
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7088Compounds having three or more nucleosides or nucleotides
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
Applicants
  • 天津医科大学总医院 TIANJIN MEDICAL UNIVERSITY GENERAL HOSPITAL [CN]/[CN]
  • 北京市神经外科研究所 BEIJING NEUROSURGICAL INSTITUTE [CN]/[CN]
Inventors
  • 康春生 KANG, Chunsheng
  • 江涛 JIANG, Tao
Agents
  • 上海光华专利事务所(普通合伙) J.Z.M.C. PATENT AND TRADEMARK LAW OFFICE (GENERAL PARTNERSHIP)
Priority Data
201811473833.404.12.2018CN
Publication Language Chinese (ZH)
Filing Language Chinese (ZH)
Designated States
Title
(EN) FUNCTION AND USE OF E2F6 INHIBITOR
(FR) FONCTION ET UTILISATION D'UN INHIBITEUR D'E2F6
(ZH) E2F6抑制剂的功能与用途
Abstract
(EN)
Disclosed is a use of E2F6 as a target capable of increasing the sensitivity of temozolomide. Temozolomide is used for treating glioblastoma. E2F6 inhibitor and temozolomide treatment can increase the curability of glioblastoma. The invention provides scientific evidence for the pathogenesis and clinical treatment of glioblastoma from the clinical patient sample level, cell function level and molecular level.
(FR)
L'invention concerne une utilisation d'E2F6 en tant que cible en mesure d'augmenter la sensibilité au témozolomide. Le témozolomide est utilisé pour traiter le glioblastome. Un traitement par l'inhibiteur d'E2F6 et par le témozolomide peut augmenter la curabilité du glioblastome. L'invention fournit une preuve scientifique de la pathogenèse et du traitement clinique du glioblastome au niveau de l'échantillon clinique de patient, au niveau de la fonction cellulaire et au niveau moléculaire.
(ZH)
本发明公开了E2F6可作为能够增加替莫唑胺的敏感性的靶点,替莫唑胺用于治疗胶质母细胞瘤,E2F6抑制剂和替莫唑胺治疗可以增加对胶质母细胞瘤的治愈性。本发明从临床病人样品水平、细胞功能水平和分子水平对胶质母细胞瘤的发病机理及胶质母细胞瘤的临床治疗提供了科学证据。
Also published as
Latest bibliographic data on file with the International Bureau